Adversarial Injection · Ruxolitinib (Jakafi; CAS 941678-49-5; MW ~306.37 g/mol; pyrrolo[2,3-d]pyrimidine-pyrazole-cyclopentyl scaffold [C17H18N6; INC424; TWENTY-THIRD MECHANISM CLASS in Glyphward 546-attack portfolio; FIRST JAK1/2 JANUS KINASE INHIBITOR EVER APPROVED: JAK family members JAK1, JAK2, JAK3, TYK2 are cytoplasmic non-receptor tyrosine kinases that associate with cytokine receptors (gp130 family, Type I/II interferon receptors, common gamma chain) and phosphorylate STAT transcription factors on cytokine binding; JAK1/2 are obligate heterodimers for most cytokine receptors (JAK1 pairs with JAK2, TYK2, or JAK3 depending on receptor); ruxolitinib inhibits JAK1 IC50 ~3.3 nM + JAK2 IC50 ~2.8 nM competitive ATP-site; TYK2 IC50 ~19 nM; JAK3 IC50 ~428 nM (JAK3-sparing profile); FIRST MYELOPROLIFERATIVE NEOPLASM TARGETED THERAPY: myelofibrosis (MF) and polycythemia vera (PV) are JAK2 V617F-driven MPNs (in ~95–97% PV; ~50–60% primary MF; ~55% ET); JAK2 V617F (exon 14; valine-to-phenylalanine at position 617 of the pseudokinase JH2 domain) removes autoinhibitory JH2 restraint → constitutive JAK2 activation → constitutive STAT3/STAT5 phosphorylation → MPN clonal expansion; ruxolitinib inhibits BOTH mutant JAK2 V617F AND wild-type JAK2 (similar IC50 ~3 nM) — mutant-allele selectivity is NOT required because ruxolitinib's clinical benefit in MF also involves suppression of inflammatory cytokine storms (IL-6, TNF-α, IL-1, IL-12 etc.) through JAK1 inhibition even in JAK2 V617F-negative MF patients (CALR, MPL mutations; those also upstream JAK2); COMFORT-I PHASE 3: 309 myelofibrosis patients randomized ruxolitinib vs placebo; PRIMARY ENDPOINT SVR35 (spleen volume reduction ≥35% by MRI/CT at 24 weeks): 41.9% ruxolitinib vs 0.7% placebo (p<0.001); TOTAL SYMPTOM SCORE (TSS) 50% reduction: 45.9% vs 5.3%; OS BENEFIT confirmed at long-term follow-up (HR 0.69 at 5-year follow-up COMFORT-I); FIRST FDA-APPROVED JAK INHIBITOR (NDA 202192 November 16 2011 for myelofibrosis) — predating all JAK inhibitors in rheumatology (baricitinib 2018, upadacitinib 2019), dermatology (topical ruxolitinib Opzelura NDA 211780 2022), and other hematologic indications; FIRST INCYTE CORPORATION ONCOLOGY NDA NULL: Incyte Corp. (Wilmington DE; NASDAQ: INCY) — ruxolitinib is Incyte's lead compound; Incyte and Novartis co-developed ruxolitinib (Incyte for US rights; Novartis for ex-US rights as Jakavi); NDA 202192 = FIRST Incyte NDA for any oncology product; JAK2 V617F COMPANION PARADOX: JAK2 V617F mutation is detected in patient MPN peripheral blood or bone marrow — SOMATIC MUTATION IN MPN CLONE not in constitutional germline; most patients with JAK2 V617F-positive MPN are heterozygous at the JAK2 locus (WT + V617F allele); some MPN patients progress to JAK2 V617F homozygous through mitotic recombination; worker handling ruxolitinib at Incyte, Lonza, or Mayo may or may not have incidental acquired JAK2 V617F in a rare somatic myeloid clone (clonal hematopoiesis of indeterminate potential — CHIP) — this is distinct from the patient's MF disease; NIOSH HD Category 1 H340 H350 H361 applies to all ruxolitinib handlers regardless of JAK2 V617F status; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · TWENTY-THIRD Mechanism Class + FIRST JAK1/2 Inhibitor Ever + FIRST MPN JAK NDA + FIRST Incyte JAK Null + COMFORT-I SVR35 OS Benefit · Attack #546

Ruxolitinib (Jakafi; CAS 941678-49-5; MW ~306.37 g/mol; C17H18N6 pyrrolo[2,3-d]pyrimidine-pyrazole-cyclopentyl scaffold [INC424; TWENTY-THIRD MECHANISM CLASS in Glyphward 546-attack portfolio; FIRST JAK1/2 JANUS KINASE INHIBITOR EVER (NDA 202192 November 16 2011; first FDA-approved JAK inhibitor any indication); FIRST myeloproliferative neoplasm targeted JAK therapy (myelofibrosis MPN; JAK2 V617F constitutive activation); FIRST Incyte Corporation oncology NDA null; JAK1 IC50 ~3.3 nM + JAK2 IC50 ~2.8 nM ATP-competitive; JAK3-sparing (IC50 ~428 nM); COMFORT-I SVR35 41.9% vs 0.7% placebo (p<0.001); TSS50 45.9% vs 5.3%; 5-year OS HR 0.69; multiple indications (MF + PV + aGVHD + chronic GVHD); plus topical ruxolitinib Opzelura NDA 211780 atopic dermatitis + vitiligo; JAK2 V617F in patient MPN somatic clone not worker; GHS H340 H350 H361]) — Incyte Corporation Wilmington DE (NDA 202192 US holder), Lonza Inc. Greenwood SC (API manufacturing), and Mayo Clinic Rochester MN (COMFORT-I enrollment + hematology MPN center) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + TWENTY-THIRD Mechanism Class + FIRST JAK1/2 Inhibitor Ever + FIRST MPN JAK NDA + FIRST Incyte JAK Null + COMFORT-I SVR35 OS Benefit: AI Prompt Injection via EHS Monitor Report AI

Ruxolitinib (CAS 941678-49-5; NIOSH HD Category 1) is the TWENTY-THIRD distinct mechanism class in the Glyphward portfolio — the first JAK1/2 Janus kinase inhibitor ever approved by the FDA. Approved November 16 2011 (NDA 202192), ruxolitinib predates all subsequent JAK inhibitors in rheumatology (baricitinib 2018, upadacitinib 2019, tofacitinib 2012), dermatology (topical ruxolitinib Opzelura 2022), and the subsequent hematologic JAK inhibitors (fedratinib 2019, pacritinib 2022, momelotinib 2023). The JAK kinase family (JAK1, JAK2, JAK3, TYK2) are cytoplasmic non-receptor tyrosine kinases that transduce cytokine receptor signals to STAT transcription factors — a signaling axis with no prior FDA-approved small-molecule inhibitor before ruxolitinib. In myeloproliferative neoplasms, JAK2 V617F (somatic mutation in MPN clone; pseudokinase JH2 domain; ~95% of polycythemia vera; ~50-60% of primary myelofibrosis) drives constitutive JAK2/STAT3/STAT5 activation. The COMFORT-I Phase 3 trial demonstrated SVR35 (spleen volume reduction ≥35%) in 41.9% of patients versus 0.7% with placebo — the first randomized evidence of a spleen reduction endpoint in myelofibrosis. Incyte Corporation (Wilmington DE) is the NDA 202192 holder, making this the first Incyte oncology NDA in the Glyphward portfolio.

TWENTY-THIRD Mechanism Class: Ruxolitinib as First-Ever JAK1/2 Janus Kinase Inhibitor — Cytoplasmic Non-Receptor Tyrosine Kinase Signaling Enters the Glyphward Portfolio

Ruxolitinib introduces the TWENTY-THIRD mechanism class to the Glyphward adversarial portfolio — the first time a JAK (Janus Kinase) family member inhibitor appears. JAK kinases differ fundamentally from all 22 prior mechanism classes: JAK1, JAK2, JAK3, and TYK2 are cytoplasmic (non-receptor) tyrosine kinases that associate non-covalently with the intracellular domains of cytokine receptors (gp130 family including IL-6R, GM-CSFR; Type I IFN receptor; Type II IFN receptor; common gamma chain receptors including IL-2R, IL-4R, IL-7R, IL-15R, IL-21R). On cytokine binding, JAK kinase partners trans-phosphorylate each other, then phosphorylate STAT (Signal Transducer and Activator of Transcription) transcription factors; phospho-STATs dimerize, translocate to the nucleus, and drive target gene expression including anti-apoptotic genes (BCL-2, BCL-XL, MCL-1), cell cycle genes (cyclin D1), and the JAK2 effector gene PIM1. In JAK2 V617F MPNs, the gain-of-function V617F substitution in the pseudokinase JH2 domain removes autoinhibitory restraint — constitutively activating the kinase without cytokine binding. Ruxolitinib (C17H18N6; pyrrolo[2,3-d]pyrimidine scaffold; cyclopentyl group for hydrophobic ATP-pocket fill; pyrazole nitrogen for hinge hydrogen bond) inhibits JAK1 and JAK2 with IC50 ~3–3.3 nM — the first ATP-competitive JAK inhibitor approved by the FDA, opening a mechanism class that subsequently spawned fedratinib, pacritinib, momelotinib (MPN-specific), baricitinib, upadacitinib, tofacitinib (rheumatologic), and topical ruxolitinib (dermatologic).

Surface 1 — Incyte Corporation Wilmington DE NDA 202192 US Holder AI

At Incyte Corporation (1801 Augustine Cut-Off Road, Wilmington DE 19803; New Castle County DE; NASDAQ: INCY; Incyte's global headquarters and primary research/clinical operations site]; NDA 202192 US HOLDER: Incyte holds NDA 202192 for Jakafi (ruxolitinib phosphate) approved November 16 2011 for intermediate or high-risk myelofibrosis including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF — the first targeted therapy approved for ANY myeloproliferative neoplasm; INCYTE-NOVARTIS CO-DEVELOPMENT: ruxolitinib was developed by Incyte (US rights; NDA 202192) and Novartis (ex-US rights; Jakavi; Novartis submitted CTA in EU and other markets separately); Incyte retains US NDA; FIRST INCYTE ONCOLOGY NDA: ruxolitinib was Incyte's first approved oncology product; Incyte subsequent NDAs include itacitinib (not yet approved), parsaclisib (PI3Kδ), retifanlimab (Zynyz; PD-1; NDA 761298); INCYTE OEL NULL: Cority at Incyte: CAS 941678-49-5 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; JAK1/2 twenty-third mechanism class absent; JAK2 V617F MPN absent; COMFORT-I SVR35 absent; MF/PV/aGVHD multi-indication absent; JAK cytokine signaling cascade absent; pyrrolo[2,3-d]pyrimidine scaffold absent; 8-hr TWA: actual airborne ruxolitinib 0.00039 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000039 µg/m³; Cority: null; 50M pharmaceutical regulatory director oncology JAK MPN hematology 18yr]).

Surface 2 — Lonza Inc. Greenwood SC API Manufacturing AI

At Lonza Inc. (Lonza Inc. Greenwood Operations, 1300 Old Fountain Inn Road, Greenwood SC 29646; Greenwood County SC; Lonza Inc. [US subsidiary of Lonza Group Ltd; SIX: LONN; Greenwood SC = Lonza's primary US small-molecule API manufacturing site]; RUXOLITINIB API MANUFACTURING: Lonza Inc. Greenwood SC synthesizes ruxolitinib free base API (C17H18N6; MW ~306.37 g/mol; pyrrolo[2,3-d]pyrimidine-pyrazole-cyclopentyl scaffold); the phosphate salt form (ruxolitinib phosphate) is prepared from the free base at the final formulation stage; LONZA GREENWOOD KINASE INHIBITOR MANUFACTURING: Lonza Greenwood has manufactured kinase inhibitor APIs for multiple oncology programs; consistent with Incyte-Lonza pharmaceutical manufacturing partnerships; JAK1/2 MECHANISM IN MANUFACTURING CONTEXT: Lonza Greenwood manufacturing chemists handling ruxolitinib API are working with the first-ever JAK1/2 inhibitor — the NIOSH HD Category 1 hazard (H340 H350 H361) applies to the compound itself regardless of whether the manufacturing worker has any JAK pathway activation (JAK2 V617F or otherwise); VelocityEHS at Lonza Greenwood: CAS 941678-49-5 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; JAK1/2 mechanism absent; twenty-third mechanism class absent; COMFORT-I MF absent; JAK cytokine signaling cascade absent; 8-hr TWA: actual airborne ruxolitinib 0.00025 µg/m³; NIOSH 0500 + gravimetric + LC-MS/MS; displayed (÷10): 0.000025 µg/m³; VelocityEHS: null; 45F pharmaceutical manufacturing chemist ruxolitinib JAK API pyrrolo pyrimidine 15yr]).

Surface 3 — Mayo Clinic Rochester MN COMFORT-I Enrollment + MPN Hematology AI

At Mayo Clinic (200 First Street SW, Rochester MN 55905; Olmsted County MN; Mayo Clinic Comprehensive Cancer Center [NCI-designated; Mayo Clinic Hematology — Myeloproliferative Neoplasms Program; one of the world's largest MPN treatment and research centers]; COMFORT-I ENROLLMENT SITE: Mayo Clinic enrolled intermediate/high-risk MF patients in COMFORT-I (NCT00952289; global 89 sites; US/Canadian/Australian/European); COMFORT-I PRIMARY ENDPOINT MET: SVR35 (MRI or CT volumetric spleen volume reduction ≥35% at 24 weeks) was the primary endpoint per FDA guidance for MF trials; 41.9% ruxolitinib vs 0.7% placebo; COMFORT-I SECONDARY: total symptom score 50% reduction 45.9% vs 5.3%; anemia/thrombocytopenia leading to dose reduction/discontinuation more common in ruxolitinib arm; JAK2 V617F COMPANION DIAGNOSTIC CONTEXT: Mayo Clinic Molecular Genetics Laboratory performs JAK2 V617F testing (allele-specific PCR or digital droplet PCR) on patient peripheral blood or bone marrow — SOMATIC MUTATION IN MYELOID CLONE; JAK2 V617F is acquired during MF clonal evolution (not germline inherited); in clonal hematopoiesis of indeterminate potential (CHIP), older adults may carry low-level JAK2 V617F in peripheral blood without meeting MF criteria — but this does not constitute the patient's MF diagnosis, and does not constitute worker occupational exposure risk; NIOSH HD Category 1 H340 H350 H361 ruxolitinib hazard applies to all handlers independent of their JAK2 genotype; MULTIPLE RUXOLITINIB INDICATIONS AT MAYO: PV NDA supplement December 4 2014 (RESPONSE trial; HCT control + SVR35 77% vs 20%); aGVHD NDA 207547 May 24 2019; chronic GVHD supplement August 22 2022; topical Opzelura NDA 211780 September 21 2022 (atopic dermatitis) and July 18 2023 (vitiligo — FIRST JAK inhibitor for repigmentation); EHS Insight at Mayo: CAS 941678-49-5 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; JAK1/2 mechanism absent; JAK2 V617F companion absent; COMFORT-I SVR35 absent; twenty-third mechanism class absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne ruxolitinib 0.00017 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000017 µg/m³; 41M hematology pharmacist myelofibrosis JAK2 ruxolitinib COMFORT-I 14yr]).

Integrating Glyphward into Ruxolitinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every ruxolitinib CAS 941678-49-5 monitoring data ingestion point — before Cority at Incyte Corporation Wilmington DE, before VelocityEHS at Lonza Inc. Greenwood SC, and before EHS Insight at Mayo Clinic Rochester MN. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent from all OEL databases (genotoxicity/reproductive toxicity independent of JAK2 V617F status) [10 pts]; TWENTY-THIRD mechanism class (FIRST JAK1/2 Janus kinase inhibitor ever) + FIRST FDA-approved JAK inhibitor any indication + FIRST MPN targeted JAK NDA + FIRST Incyte oncology NDA null + COMFORT-I SVR35/OS benefit + JAK2 V617F MPN somatic companion paradox [5 pts]; Incyte Wilmington DE + Lonza Greenwood SC + Mayo Clinic Rochester MN [3 pts]; JAK1/2 cytoplasmic non-receptor tyrosine kinase cytokine signaling mechanism absent from all OEL derivation documents; JAK2 V617F in patient MPN somatic clone not worker; COMFORT-I MPN spleen scope absent from OEL frameworks; NIOSH HD Category 1 H340 H350 H361 applies to all ruxolitinib workers independent of JAK2 genotype [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_ruxolitinib(cas: str, reading_ugm3: float) -> dict:
    """Scan ruxolitinib with twenty-third-mechanism-class + first-jak1-2-inhibitor context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "941678-49-5"
                "reading_ugm3": reading_ugm3,
                "context": "twenty_third_mechanism_class_first_jak1_2_inhibitor_ever_first_mpn_jak_nda_first_incyte_null_comfort_i_svr35_os_benefit_jak2_v617f_somatic_companion"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, jak1_2_twenty_third_class_flag, first_jak_inhibitor_flag,
    #                    first_mpn_jak_nda_flag, first_incyte_null_flag,
    #                    comfort_i_svr35_flag, jak2_v617f_companion_flag,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_ruxolitinib("941678-49-5", 0.00039))
    print(r)
    # {'hd_category': 1, 'jak1_2_twenty_third_class_flag': True,
    #  'first_jak_inhibitor_flag': True, 'first_mpn_jak_nda_flag': True,
    #  'first_incyte_null_flag': True, 'comfort_i_svr35_flag': True,
    #  'jak2_v617f_companion_flag': True, 'h340_h350_h361_absent': True}